For example, highly selective CaMKII inhibitors are now in development: Cardurion’s first-in-class molecules (e.g., CRD-2015, CRD-2959) demonstrated a potent inhibition of CaMKII targets and improved survival in preclinical HF models [37], and a lead agent has already entered Phase 1 trials (with plans to expand into HF indications) [37]. This evidence concerns the gene CAMK2G and hydrops fetalis.